Navigation Links
New study shows Dermytol produces pronounced decrease in malignant melanoma tumor volume

SAN DIEGO, CA., April 7 . . .A new study presented at the Experimental Biology Annual Meeting shows that a proprietary blend extracted from canola, Dermytol, produces a pronounced reduction of malignant melanoma cell growth. Dermytol, a proprietary compound developed by KGK Synergize Inc., a biotechnology company in Ontario Canada, is designed to protect skin cells from damage that may lead to skin cancer.

Mal Evans, DVM, MSc, PhD, KGK Synergize Incs Scientific Director, said, Skin cancer rates have been rising, and we are likely to see that continue as the population ages. The National Cancer Institute (NCI) estimates that more than 62,000 Americans will be diagnosed with melanoma and one million Americans will be diagnosed with non-melanoma skin cancer this year. NCI expects more than 8,000 deaths from melanoma and less than 1,000 deaths from non-melanoma cancers this year.

Dermytol has the potential to be used in anti-aging and sun-protection products to reduce damage to skin. Results of preclinical trials in animals have been promising leading to human trials now running in both Canada and the United States.

In the most recent study, male mice were fed either a Dermytol-canola oil mixture or just canola oil. In a separate part of the study, researchers applied either a Dermytol cream or a placebo cream onto the shaved skin of a different group of mice. After seven days of treatment, all of the mice were injected with malignant melanoma tumor cells. Dermytol or placebo treatments continued for 25 days.

The mice in both Dermytol groups benefited from their treatments. Compared to the controls, the orally treated mice showed an average decrease in tumor size by about 45 percent. The mice receiving the topical treatment benefited even more with a 61 percent decrease in tumor volume.

In this study and previous preclinical studies, Dermytol produced no adverse effects.

In a laboratory cell culture study, Dermytol inhibited the proliferation of human cancer cells.

In another study, dietary supplementation with Dermytol moderately delayed the onset of skin tumors and significantly reduced tumor growth rate in mice treated to induce non-melanoma skin cancers.

A trial involving 45 subjects with actinic keratoses precancerous skin lesions is underway. The current treatment for actinic keratoses is removal by freezing which can be painful or the application of a cream that causes inflammation and blistering of the skin, said Evans. We expect Dermytol to be a welcome option.


Contact: Jeff Nedelman
Strategic Communications

Related biology news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. Study begins to reveal clues to the cause and progression of sepsis
4. Clones on task serve greater good, evolutionary study shows
5. New study warns limited carbon market puts 20 percent of tropical forest at risk
6. New study examines how rearing environment can alter navigation
7. Study links cat disease to flame retardants in furniture and to pet food
8. New continent and species discovered in Atlantic study
9. Study shows link between alcohol consumption and hiv disease progression
10. Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures
11. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
Post Your Comments:
(Date:10/26/2015)... Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern authentication ... , today announced the launch of its latest version ... unified platform enabling organizations to use standards-based authentication that ... Nok Nok S3 Authentication Suite is ideal for organizations ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... Mass., Oct. 22, 2015  Aware, Inc. (NASDAQ: AWRE ), ... results for its third quarter ended September 30, 2015.  ... quarter of 2015 was $4.0 million, a decrease of 33% compared ... in the third quarter of 2015 was $2.2 million, or $0.10 ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
Breaking Biology Technology: